AGIO · Agios Pharmaceuticals Inc
United States · RS rating 61 · As of 2026-11-03
| Price | 31.20 USD |
|---|---|
| 1-day change | +4.2% |
| RS rating (overall / 1M / 3M / 12M) | 61 / 56 / 63 / 32 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 36 / 38 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | +55.0% |
| Distance from 52-week high | +31.4% |
| Market cap (USD) | $1.5B |